Taxonomic group: bacteria / Firmicutes
(Phylum: Firmicutes)
Host organism: Homo sapiens
Associated disease: septicemia [ICD11:
MA15.Y 
];
meningitis [ICD11:
1D01 ];
infection due to Streptococcus pneumoniae [ICD11:
XN3PW ]
The structure was elucidated in this paperNCBI PubMed ID: 27818299Publication DOI: 10.1016/j.chembiol.2016.09.016Journal NLM ID: 101676030Publisher: Cambridge,MA : Cell Press
Correspondence: peter.seeberger
mpikg.mpg.de; martin.witzenrath
charite.de
Institutions: Institute of Chemistry and Biochemistry, Freie Universitat Berlin, Arnimallee 22, 14195 Berlin, Germany, Department of Biomolecular Systems, Max-Planck Institute of Colloids and Interfaces, Am Mühlenberg 1, 14476 Potsdam, Germany, Department of Infectious Diseases and Pulmonary Medicine, Charité - Universitätsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany, Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461, USA, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity.
Streptococcus pneumoniae, glycoconjugate vaccines, Epitope Mapping, Glycan arrays, Opsonophagocytosis, Synthetic glycans
Structure type: oligomer ; 422.1291 [M+Na]+
C
14H
25NO
12Location inside paper: p.1408, fig.1 compound 4
Compound class: CPS
Contained glycoepitopes: IEDB_115136,IEDB_120354,IEDB_140630,IEDB_142488,IEDB_146664,IEDB_423153,IEDB_983931,SB_192
Methods: 13C NMR, 1H NMR, NMR-2D, IR, SDS-PAGE, TLC, ELISA, chemical synthesis, MALDI-TOF MS, biological assays, serological methods, HPLC, UV, glycosylation, cytokine analysis, optical rotation measurement, statistical analysis, binding assays, immunization, conjugation, microarray analysis, flow cytometry
Synthetic data: chemical
Comments, role: synthetic disaccharide 4 fragment of CPS repeating units
Related record ID(s): 12022
NCBI Taxonomy refs (TaxIDs): 1313
Show glycosyltransferases
NMR conditions: in D2O
1H NMR data: present in publication
|
13C NMR data: present in publication
|
There is only one chemically distinct structure:
Found 
report error